Expression of GPR55 and either cannabinoid CB1 or CB2 heteroreceptor complexes in the caudate, putamen, and accumbens nuclei of control, parkinsonian, and dyskinetic non-human primates
- PMID: 32691218
- DOI: 10.1007/s00429-020-02116-4
Expression of GPR55 and either cannabinoid CB1 or CB2 heteroreceptor complexes in the caudate, putamen, and accumbens nuclei of control, parkinsonian, and dyskinetic non-human primates
Abstract
Endocannabinoids are neuromodulators acting on specific cannabinoid CB1 and CB2 G-protein-coupled receptors (GPCRs), representing potential therapeutic _targets for neurodegenerative diseases. Cannabinoids also regulate the activity of GPR55, a recently "deorphanized" GPCR that directly interacts with CB1 and with CB2 receptors. Our hypothesis is that these heteromers may be taken as potential _targets for Parkinson's disease (PD). This work aims at assessing the expression of heteromers made of GPR55 and CB1/CB2 receptors in the striatum of control and parkinsonian macaques (with and without levodopa-induced dyskinesia). For this purpose, double blind in situ proximity ligation assays, enabling the detection of GPCR heteromers in tissue samples, were performed in striatal sections of control, MPTP-treated and MPTP-treated animals rendered dyskinetic by chronic treatment with levodopa. Image analysis and statistical assessment were performed using dedicated software. We have previously demonstrated the formation of heteromers between GPR55 and CB1 receptor (CB1-GPR55_Hets), which is highly expressed in the central nervous system (CNS), but also with the CB2 receptor (CB2-GPR55_Hets). Compared to the baseline expression of CB1-GPR55_Hets in control animals, our results showed increased expression levels in basal ganglia input nuclei of MPTP-treated animals. These observed increases in CB1-GPR55_Hets returned back to baseline levels upon chronic treatment with levodopa in dyskinetic animals. Obtained data regarding CB2-GPR55_Hets were quite similar, with somehow equivalent amounts in control and dyskinetic animals, and with increased expression levels in MPTP animals. Taken together, the detected increased expression of GPR55-endocannabinoid heteromers appoints these GPCR complexes as potential non-dopaminergic _targets for PD therapy.
Keywords: G-protein coupled receptor (GPCR) heteromer; Levodopa; Parkinson’s disease; Proximity ligation assay (PLA); Striatum.
Similar articles
-
Expression of cannabinoid CB1 R-GPR55 heteromers in neuronal subtypes of the Macaca fascicularis striatum.Ann N Y Acad Sci. 2020 Sep;1475(1):34-42. doi: 10.1111/nyas.14413. Epub 2020 Jun 27. Ann N Y Acad Sci. 2020. PMID: 32594556
-
Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB1 and CB2 receptors and relevance for Alzheimer's disease and levodopa-induced dyskinesia.Brain Behav Immun. 2018 Jan;67:139-151. doi: 10.1016/j.bbi.2017.08.015. Epub 2017 Aug 24. Brain Behav Immun. 2018. PMID: 28843453
-
The cannabinoid CB1 receptor interacts with the angiotensin AT2 receptor. Overexpression of AT2-CB1 receptor heteromers in the striatum of 6-hydroxydopamine hemilesioned rats.Exp Neurol. 2023 Apr;362:114319. doi: 10.1016/j.expneurol.2023.114319. Epub 2023 Jan 9. Exp Neurol. 2023. PMID: 36632949
-
The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson's disease.Prog Neuropsychopharmacol Biol Psychiatry. 2020 Jan 10;96:109745. doi: 10.1016/j.pnpbp.2019.109745. Epub 2019 Aug 20. Prog Neuropsychopharmacol Biol Psychiatry. 2020. PMID: 31442553 Review.
-
GPR55 - a putative "type 3" cannabinoid receptor in inflammation.J Basic Clin Physiol Pharmacol. 2016 May 1;27(3):297-302. doi: 10.1515/jbcpp-2015-0080. J Basic Clin Physiol Pharmacol. 2016. PMID: 26669245 Review.
Cited by
-
Cannabinoids: Potential for Modulation and Enhancement When Combined with Vitamin B12 in Case of Neurodegenerative Disorders.Pharmaceuticals (Basel). 2024 Jun 20;17(6):813. doi: 10.3390/ph17060813. Pharmaceuticals (Basel). 2024. PMID: 38931480 Free PMC article. Review.
-
Endocannabinoid signaling pathways: beyond CB1R and CB2R.J Cell Commun Signal. 2021 Sep;15(3):335-360. doi: 10.1007/s12079-021-00622-6. Epub 2021 May 12. J Cell Commun Signal. 2021. PMID: 33978927 Free PMC article. Review.
-
Regulation of Expression of Cannabinoid CB2 and Serotonin 5HT1A Receptor Complexes by Cannabinoids in Animal Models of Hypoxia and in Oxygen/Glucose-Deprived Neurons.Int J Mol Sci. 2022 Aug 26;23(17):9695. doi: 10.3390/ijms23179695. Int J Mol Sci. 2022. PMID: 36077095 Free PMC article.
-
The Binding Mode to Orthosteric Sites and/or Exosites Underlies the Therapeutic Potential of Drugs _targeting Cannabinoid CB2 Receptors.Front Pharmacol. 2022 Feb 16;13:852631. doi: 10.3389/fphar.2022.852631. eCollection 2022. Front Pharmacol. 2022. PMID: 35250601 Free PMC article. Review.
-
Membrane Heteroreceptor Complexes as Second-Order Protein Modulators: A Novel Integrative Mechanism through Allosteric Receptor-Receptor Interactions.Membranes (Basel). 2024 Apr 25;14(5):96. doi: 10.3390/membranes14050096. Membranes (Basel). 2024. PMID: 38786931 Free PMC article.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources